<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03468413</url>
  </required_header>
  <id_info>
    <org_study_id>CP1050-E101</org_study_id>
    <nct_id>NCT03468413</nct_id>
  </id_info>
  <brief_title>A First-in-human Phase 1 Study of CP1050</brief_title>
  <official_title>A Randomised, First-in-human, Double-blinded, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CP1050 in Healthy Subjects; Including the Effect of Food and Gender on the Pharmacokinetics and Pharmacodynamics of a Single Dose of CP1050 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Curadim Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Curadim Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, first-in-human, double-blind, single-centre, randomised,
      placebo-controlled, single and multiple oral dose study in healthy subjects conducted in 4
      parts (Part 1; Single-ascending dose, Part 2; Food-effect evaluation, Part 3; Gender-effect
      evaluation, Part 4; Multiple-ascending dose).
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of any drug-related adverse events</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal vital signs (systolic and diastolic blood pressure, pulse rate, respiratory rate and oral body temperature)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of vital signs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal clinical laboratory tests (including clinical chemistry, haematology and urinalysis)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of clinical laboratory tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal 12-lead safety ECG (including heart rate, RR interval, PR interval, QRS duration, QT interval, and QT interval corrected for heart rate using Fridericia's method [QTcF])</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of 12-lead safety ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal 12-lead continuous (24-hour) ECG (including mean hourly heart rate and incidence of arrhythmia assessed as per the ECG Alert Criteria)</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of 12-lead continuous (24-hour) ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal Pulmonary function tests (including FEV1, FVC, FEF25-75 and DLCO [Part 4 only])</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of pulmonary function tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal ophthalmological findings assessed by fundoscopy or OCT</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of ophthalmological assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal physical examinations</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>To evaluate the safety and tolerability of CP1050 in comparison with placebo after a single oral dose and multiple oral doses in healthy subjects in terms of physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma terminal elimination half-life (T1/2)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lowest absolute value of lymphocytes at postdose (nadir)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The lowest percentage of baseline (nadir [%])</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of nadir (Tnadir)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the effectiveness curve (AUCE)</measure>
    <time_frame>Up to 21 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Single ascending dose, CP1050 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple ascending dose, CP1050 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP1050 or Placebo</intervention_name>
    <description>Randomised, double-blinded, placebo-controlled</description>
    <arm_group_label>Single ascending dose, CP1050 or Placebo</arm_group_label>
    <arm_group_label>Multiple ascending dose, CP1050 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian males or females between 18 and 55 years of age (inclusive).

          -  A body weight of ≥60 kg for males and ≥50 kg for females, with a body mass index (BMI)
             ranging from 18.0 to 30.0 kg/m2 (inclusive).

          -  Healthy and free from clinically significant illness or disease.

        Exclusion Criteria:

          -  Presence or history of any clinically significant disease that could interfere with
             the objectives of the study or the safety of the subject in the opinion of the
             Investigator.

          -  Participation in more than 3 clinical studies involving administration of an IMP in
             the past one year, or any study within 12 weeks.

          -  Clinically significant abnormalities in ECG or laboratory tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit (CRU) Ltd.</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2018</study_first_posted>
  <last_update_submitted>March 11, 2018</last_update_submitted>
  <last_update_submitted_qc>March 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP1050</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Healthy subjects</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

